Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes Undergoing PCI: A Long Way to Select Optimal Agent and Route
Figure 1
Comparison between eptifibatide and tirofiban patients shows a continuous decreasing hazard rate, from immediately after percutaneous coronary intervention to one year afterwards, in the tirofiban group. Eptifibatide patients have two late phases of hazard rate increase. This experience is from the study by Schiariti et al. [32].
